SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Wei-Tien Tai, Chung-Wai Shiau, Yong-Shi Li, Chun-Wei Chang, Jui-Wen Huang, Ting-Ting Hsueh, Hui-Chuan Yu, Kuen-Feng Chen, Nintedanib (BIBF-1120) inhibits hepatocellular carcinoma growth independent of angiokinase activity, Journal of Hepatology, 2014, 61, 1, 89

    CrossRef

  2. 2
    Claudia Fumarola, Cristina Caffarra, Silvia La Monica, Maricla Galetti, Roberta R. Alfieri, Andrea Cavazzoni, Elena Galvani, Daniele Generali, Pier Giorgio Petronini, Mara A. Bonelli, Effects of sorafenib on energy metabolism in breast cancer cells: role of AMPK–mTORC1 signaling, Breast Cancer Research and Treatment, 2013, 141, 1, 67

    CrossRef

  3. 3
    Niranjan Awasthi, Changhua Zhang, Stefan Hinz, Margaret A Schwarz, Roderich E Schwarz, Enhancing sorafenib-mediated sensitization to gemcitabine in experimental pancreatic cancer through EMAP II, Journal of Experimental & Clinical Cancer Research, 2013, 32, 1, 12

    CrossRef

  4. 4
    Dipti K. Pawaskar, Robert M. Straubinger, Gerald J. Fetterly, Wen W. Ma, William J. Jusko, Interactions of Everolimus and Sorafenib in Pancreatic Cancer Cells, The AAPS Journal, 2013, 15, 1, 78

    CrossRef

  5. 5
    Weifeng Zhang, Minghui Wan, Lunchao Ma, Xiang Liu, Jianxing He, Protective effects of ADAM8 against cisplatin-mediated apoptosis in non-small-cell lung cancer, Cell Biology International, 2013, 37, 1
  6. 6
    A. B. El-Khoueiry, R. K. Ramanathan, D. Y. Yang, W. Zhang, S. Shibata, J. J. Wright, D. Gandara, H. J. Lenz, A randomized phase II of gemcitabine and sorafenib versus sorafenib alone in patients with metastatic pancreatic cancer, Investigational New Drugs, 2012, 30, 3, 1175

    CrossRef

  7. 7
    A. Goncalves, M. Gilabert, E. Francois, L. Dahan, H. Perrier, R. Lamy, D. Re, R. Largillier, M. Gasmi, X. Tchiknavorian, B. Esterni, D. Genre, L. Moureau-Zabotto, M. Giovannini, J.-F. Seitz, J.-R. Delpero, O. Turrini, P. Viens, J.-L. Raoul, BAYPAN study: a double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic cancer, Annals of Oncology, 2012, 23, 11, 2799

    CrossRef

  8. 8
    Sanne Hindriksen, Maarten F. Bijlsma, Cancer Stem Cells, EMT, and Developmental Pathway Activation in Pancreatic Tumors, Cancers, 2012, 4, 4, 989

    CrossRef

  9. 9
    Marie-José Blivet-Van Eggelpoël, Hamza Chettouh, Laetitia Fartoux, Lynda Aoudjehane, Véronique Barbu, Colette Rey, Sabrina Priam, Chantal Housset, Olivier Rosmorduc, Christèle Desbois-Mouthon, Epidermal growth factor receptor and HER-3 restrict cell response to sorafenib in hepatocellular carcinoma cells, Journal of Hepatology, 2012, 57, 1, 108

    CrossRef

  10. 10
    Melchiorre Cervello, Dimcho Bachvarov, Nadia Lampiasi, Antonella Cusimano, Antonina Azzolina, James A. McCubrey, Giuseppe Montalto, Molecular mechanisms of sorafenib action in liver cancer cells, Cell Cycle, 2012, 11, 15, 2843

    CrossRef

  11. 11
    Pelin Cinar, Margaret A. Tempero, Monoclonal Antibodies and Other Targeted Therapies for Pancreatic Cancer, The Cancer Journal, 2012, 18, 6, 653

    CrossRef

  12. 12
    Do-Hee Kim, Taebo Sim, Novel small molecule Raf kinase inhibitors for targeted cancer therapeutics, Archives of Pharmacal Research, 2012, 35, 4, 605

    CrossRef

  13. You have free access to this content13
    Sonshin Takao, Qiang Ding, Shyuichiro Matsubara, Pancreatic cancer stem cells: regulatory networks in the tumor microenvironment and targeted therapy, Journal of Hepato-Biliary-Pancreatic Sciences, 2012, 19, 6
  14. 14
    Robert J. Amato, Amber L. Flaherty, Mika Stepankiw, Phase I Trial of Everolimus Plus Sorafenib for Patients with Advanced Renal Cell Cancer, Clinical Genitourinary Cancer, 2012, 10, 1, 26

    CrossRef

  15. 15
    Joan Fernando, Patricia Sancho, Conrado M. Fernández-Rodriguez, José L. Lledó, Laia Caja, Jean S. Campbell, Nelson Fausto, Isabel Fabregat, Sorafenib sensitizes hepatocellular carcinoma cells to physiological apoptotic stimuli, Journal of Cellular Physiology, 2012, 227, 4
  16. 16
    Vijay Ramakrishnan, Michael Timm, Jessica L. Haug, Teresa K. Kimlinger, Timothy Halling, Linda E. Wellik, Thomas E. Witzig, S. Vincent Rajkumar, Alex A. Adjei, Shaji Kumar, Sorafenib, a multikinase inhibitor, is effective in vitro against non-hodgkin lymphoma and synergizes with the mTOR inhibitor rapamycin, American Journal of Hematology, 2012, 87, 3
  17. 17
    Giovanni Vitale, Silvia Zappavigna, Monica Marra, Alessandra Dicitore, Stefania Meschini, Maria Condello, Giuseppe Arancia, Sara Castiglioni, Paola Maroni, Paola Bendinelli, Roberta Piccoletti, Peter M. van Koetsveld, Francesco Cavagnini, Alfredo Budillon, Alberto Abbruzzese, Leo J. Hofland, Michele Caraglia, The PPAR-γ agonist troglitazone antagonizes survival pathways induced by STAT-3 in recombinant interferon-β treated pancreatic cancer cells, Biotechnology Advances, 2012, 30, 1, 169

    CrossRef

  18. 18
    Lei Zhang, Jia-Ning Wang, Jun-Ming Tang, Xia Kong, Jian-Ye Yang, Fei Zheng, Ling-Yun Guo, Yong-Zhang Huang, Li Zhang, Lin Tian, Shu-Fen Cao, Chang-Hai Tuo, Hong-Li Guo, Shi-You Chen, VEGF is essential for the growth and migration of human hepatocellular carcinoma cells, Molecular Biology Reports, 2012, 39, 5, 5085

    CrossRef

  19. 19
    Pedro R. Cutillas, Claus Jørgensen, Biological signalling activity measurements using mass spectrometry, Biochemical Journal, 2011, 434, 2, 189

    CrossRef

  20. You have full text access to this Open Access content20
    Aiguo Liu, Yan Liu, Zhenghu Xu, Wenying Yu, Hong Wang, Chenglong Li, Jiayuh Lin, Novel small molecule, XZH-5, inhibits constitutive and interleukin-6-induced STAT3 phosphorylation in human rhabdomyosarcoma cells, Cancer Science, 2011, 102, 7
  21. 21
    Wei-Tien Tai, Ann-Lii Cheng, Chung-Wai Shiau, Hsiang-Po Huang, Jui-Wen Huang, Pei-Jer Chen, Kuen-Feng Chen, Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma, Journal of Hepatology, 2011, 55, 5, 1041

    CrossRef

  22. 22
    Wei Zhao, Tao Zhang, Bingqian Qu, Xingxin Wu, Xu Zhu, Fanyu Meng, Yanhong Gu, Yongqian Shu, Yan Shen, Yang Sun, Qiang Xu, Sorafenib induces apoptosis in HL60 cells by inhibiting Src kinase-mediated STAT3 phosphorylation, Anti-Cancer Drugs, 2011, 22, 1, 79

    CrossRef

  23. 23
    Yasunobu Matsuda, Manabu Fukumoto, Sorafenib: complexities of Raf-dependent and Raf-independent signaling are now unveiled, Medical Molecular Morphology, 2011, 44, 4, 183

    CrossRef

  24. 24
    Ansgar Brüning, Petra Burger, Marianne Vogel, Andrea Gingelmaier, Klaus Friese, Alexander Burges, Nelfinavir induces mitochondria protection by ERK1/2-mediated mcl-1 stabilization that can be overcome by sorafenib, Investigational New Drugs, 2010, 28, 5, 535

    CrossRef

  25. 25
    Yan Wang, Juncha Gao, Di Zhang, Jian Zhang, Junji Ma, Huiqing Jiang, New insights into the antifibrotic effects of sorafenib on hepatic stellate cells and liver fibrosis, Journal of Hepatology, 2010, 53, 1, 132

    CrossRef

  26. 26
    Gang Wei, Meifang Wang, Brian I. Carr, Sorafenib combined vitamin K induces apoptosis in human pancreatic cancer cell lines through RAF/MEK/ERK and c-Jun NH2-terminal kinase pathways, Journal of Cellular Physiology, 2010, 224, 1
  27. 27
    Jacek Bil, Lukasz Zapala, Dominika Nowis, Marek Jakobisiak, Jakub Golab, Statins potentiate cytostatic/cytotoxic activity of sorafenib but not sunitinib against tumor cell lines in vitro, Cancer Letters, 2010, 288, 1, 57

    CrossRef

  28. 28
    Hayato Hikita, Tetsuo Takehara, Satoshi Shimizu, Takahiro Kodama, Minoru Shigekawa, Kyoko Iwase, Atsushi Hosui, Takuya Miyagi, Tomohide Tatsumi, Hisashi Ishida, Wei Li, Tatsuya Kanto, Naoki Hiramatsu, Norio Hayashi, The Bcl-xL inhibitor, ABT-737, efficiently induces apoptosis and suppresses growth of hepatoma cells in combination with sorafenib, Hepatology, 2010, 52, 4
  29. You have free access to this content29
    Gang Wei, Meifang Wang, Terry Hyslop, Ziqiu Wang, Brian I. Carr, Vitamin K enhancement of sorafenib-mediated HCC cell growth inhibition in vitro and in vivo, International Journal of Cancer, 2010, 127, 12
  30. 30
    Austin Duffy, Shivaani Kummar, Targeting mitogen-activated protein kinase kinase (MEK) in solid tumors, Targeted Oncology, 2009, 4, 4, 267

    CrossRef